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Abstract 
Ocular manifestations are very rarely reported as side effects to checkpoint inhibitors. We pre-
sent a case of a 64-year-old Caucasian man in treatment with durvalumab for non-small-cell 
lung carcinoma who presented a retinal vasculitis with macular edema. After three boluses of 
methylprednisolone, the retinal vasculitis resolved and macular edema improved during fol-
low-up. There was no need for durvalumab to be withdrawn. © 2020 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
In recent years, checkpoint monoclonal antibodies have occupied a very significant role 
in the immune-mediated antitumor response, serving as a complement to traditional ap-
proaches to cancer. Tumor cells can mislead the immune system to downregulate its re-
sponses. Immune checkpoint drugs intervene in the immunological synapse, leading to a 
higher activation of effector T cells [1]. 
Durvalumab is one of many monoclonal antibodies approved for the treatment of urothe-
lial tumors and is currently under investigation for the treatment of other malignancies [2]. It 
is often used off-label to treat squamous carcinoma, small-cell lung cancer, and non-small-cell 
 
Case Rep Ophthalmol 2020;11:161–166 
DOI: 10.1159/000507609 © 2020 The Author(s). Published by S. Karger AG, Basel 
www.karger.com/cop 






lung carcinoma. As a programmed death-ligand 1 (PD-L1) inhibitor, durvalumab works block-
ing the interaction between programmed cell death protein (PD-1), present on T cells, and PD-
L1, present on tumor cells, resulting in a higher activity of the immune system [3]. 
The enhancement of the immune response comes with high risk for immune-related ad-
verse effects (irAEs) [2, 3]. Nevertheless, ocular side effects are seldom described in literature 
[3]. 
Case Presentation 
A 64-year-old Caucasian man presented with sudden vision loss from his left eye. He suf-
fered from non-small-cell lung carcinoma and had been in treatment with durvalumab 1,125 
mg every 3 weeks for the past 20 months. The patient had no signs of other systemic condi-
tions and his arterial blood pressure was normal. Serologies for herpes viruses, human immu-
nodeficiency virus, and T. pallidum were negative. He had no previous history of ophthalmic 
pathology. His best-corrected visual acuity (BCVA) was 20/20 in his right eye and counting 
fingers in his left eye. There were no pathological findings in the anterior segment examina-
tion. The fundoscopy showed papillitis, dot and blot hemorrhages, intraretinal hemorrhages, 
severe cystoid macular edema, and mild white sheathing in the macular vascular branches 
(Fig. 1). Posterior optical coherence tomography (Swept Source OCT, TritonTM, TOPCON, Ja-
pan) confirmed the cystoid macular edema associated with hyperreflective material that 
might be fibrin, secondary to the severe retinal inflammation, as well as vitreous hyperreflec-
tive foci. Ultra-wide-field fundus fluorescein angiography (Optos®, Optomap®, UK) revealed 
tertiary branch phlebitis and vascular leakage (Fig. 2). The patient was admitted and started 
on methylprednisolone bolus 500 mg/day for 3 days, followed by methylprednisolone 1 mg/
kg/day for 1 week, and then tapered oral prednisone, starting from 30 mg/day, over 3 weeks. 
During his admission, the patient was seen daily. In as little as 24 h after being admitted, the 
patient referred an ongoing improvement of his visual symptoms, is BCVA was 20/50 by the 
time the treatment ended, and eventually evolved to 20/25 after 2 months follow-up. During 
this time, the posterior optical coherence tomography (Swept Source OCT, TritonTM, TOPCON, 
Japan) registered a gradual reduction of the macular edema (Fig. 3) and the ultra-wide-field 
fundus fluorescein angiography (Optos®, Optomap®, UK) a resolution of the ocular vasculitis. 
After a 1-year follow-up, the patient showed a complete resolution of this condition, 
showed no signs of vasculitis or other ocular findings, had no need for rescue treatment, and 
is currently still on durvalumab without other side effects being reported. 
Discussion 
irAEs are commonly reported among patients treated with checkpoint inhibitor drugs. 
The most frequent irAEs are skin rash and diarrhea [3], although this autoimmune-like reac-
tions can occur throughout the body and produce a vast multitude of findings. Ophthalmologic 
adverse effects are reported to occur in approximately 1% of the patients, are less frequent in 
PD-L1 inhibitor drugs, when compared to other checkpoint inhibitors [3], have a time to onset 
that ranges from weeks to years after starting therapy, and do not appear to be dose related 
[2, 3]. The most frequently reported ocular findings are dry eye and uveitis [3, 4]. 
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Durvalumab has been related with keratitis and uveitis [3] but, despite that, Fang et al. 
[4] did not find any ocular manifestations related to durvalumab in the FDA’s Adverse Events 
Reporting System (FAERS). 
The immunological “handshake” between PD1/PDL1 has been described in the vasculitis 
immunological pathway [5], and checkpoint inhibitors have been suggested to trigger this vas-
cular inflammation [6]. Daxini et al. [7] demonstrated a correlation between vasculitis and 
checkpoint inhibitors like anti-PDL-1. 
Vasculitis in association with immunotherapy has been reported in other organs [8, 9]. 
Aaberg and Aaberg Jr. [10] described a case of posterior uveitis and retinal vasculitis associ-
ated with pembrolizumab, another type of checkpoint inhibitor drug, in a patient diagnosed 
with metastatic uveal melanoma witch was treated with an intraocular dexamethasone im-
plant. Acaba-Berrocal et al. [11] reported a case of a birdshot-like chorioretinopathy in a pa-
tient with cutaneous melanoma treated with pembrolizumab, which was reverted recurring 
to periocular triamcinolone. 
Ocular immune-related adverse effects are usually treated with corticosteroids, either 
topically, intraocularly, or systemically [3]. As the use of checkpoint inhibitors arises world-
wide, more and more adverse effects are being reported. Prompt diagnosis and treatment can 
lead to excellent functional prognosis without having to discontinue this vital therapy, so we 
recommend a close ophthalmological follow-up to all patients undergoing this kind of treat-
ment. In our case, retinal vasculitis recovered after three methylprednisolone boluses, with-
out being necessary to withdraw durvalumab. 
Patients with metastatic neoplasm that present ocular inflammation and vision loss must 
be referred to a complete ophthalmic examination to rule out paraneoplastic syndromes such 
as cancer-associated retinopathy (CAR), melanoma-associated retinopathy, or neoplastic ex-
udative polymorphous vitelliform maculopathy. CAR is a paraneoplastic autoimmune reti-
nopathy that consists of an immunologic process that involves retinal antigens being aber-
rantly recognized as autoantigens, leading to diffuse retinal degeneration [12]. CAR is most 
frequently associated with small-cell lung carcinoma, the usual presenting symptoms being 
subacute vision loss and visual field constriction [13]. Signs of retinal vasculitis and vitreous 
cells have been reported in CAR [14, 15], but after an initial inflammatory phase, retinal atro-
phy, retinal pigmental epithelial mottling, and arteriolar attenuation are frequent findings in 
these patients. In our case, the patient recovered promptly with no retinal damage nor vascu-
lar sequelae. 
Although the clinical case could also resemble a mild retinal vein occlusion, the presence 
of inflammatory cells in the vitreous (Fig. 3), the small number of hemorrhages, and the rapid 
recovery with systemic corticosteroid therapy made us think of a uveitic etiology. Since infec-
tious diseases were ruled out, the patient had no other clinical findings like oral or genital 
ulcers, and since it was a unilateral vasculitis with mild vitritis, we presumptively associated 
the retinal vasculitis with durvalumab. 
To our knowledge, this is the first case of vasculitis associated with durvalumab. The pa-
tient presented with ocular vasculitis and cystoid macular edema in an acute and sight-threat-
ening way, so, due to this aggressive onset, we decided to treat it with systemic corticosteroids 
bolus, having had an excellent recovery. 
Statement of Ethics 
The patient has consented to the submission and publication of the case report, images 
included. 
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Fig. 1. Color fundoscopy at presentation. Right eye shows macular microdruses. Left eye shows papillitis, 






Fig. 2. Ultra-wide-field fundus fluorescein angiography (Optos®, Optomap®, UK) shows tertiary branch 
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Fig. 3. Optical coherence tomography (Swept Source OCT, TritonTM, TOPCON, Japan) images of the macula 
(a) at presentation, (b) 24 h of follow-up, (c) 48 h of follow-up, (d) 10-day follow-up, and (e) 5-month 
follow-up. a Cystoid macular edema and subretinal fluid associated with hyperreflective subfoveal mate-
rial that can be better observed in b and c when macular edema is resolving. Vitreous hyperreflective foci 
are seen in a–d. 
 
